« Back to Record
Citation APA

Shi, W., Jiang, T., Nuciforo, P., Hatzis, C., Holmes, E., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D. D., Chia, S., Wardley, A., Ueno, T., Rossari, J., Eidtmann, H., Armour, A., Piccart-Gebhart, M., Rimm, D. D., Baselga, J., & Pusztai, L. (2019). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of oncology. doi:10.1093/annonc/mdy530


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/283374

Shi, W., Jiang, T., Nuciforo, P., Hatzis, C., Holmes, E., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D. D., Chia, S., Wardley, A., Ueno, T., Rossari, J., Eidtmann, H., Armour, A., Piccart-Gebhart, M., Rimm, D. D., Baselga, J., & Pusztai, L. (2019). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of oncology. doi:10.1093/annonc/mdy530